According to people familiar with the matter, Merck KGaA is considering divesting its biosimilars unit in light of strong competition from larger players in the sector, as reported in The New York Times.
The sources said Merck has hired an investment bank to explore a potential sale, but noted there is no guarantee that the discussions will result in any deal.
Merck's biosimilars business could be worth as much as $1 billion because of its long-term sales potential, the people added.
The unit includes a drug in advanced clinical trials that is a potential competitor to AbbVie's arthritis therapy Humira, and it also has several early-stage compounds, the news source said.
Meanwhile, Merck declined to comment on the speculation.
To read more NewsPoints articles, click here.